YRYana Rubiyana

Yana Rubiyana

*This is an algorithmically generated author record based on publicly available information.

Yana Rubiyana has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of Carbon-Dots (CDs) as Antiviral Candidates Against SARS-CoV-2 Using a Chemical Crosslinking Method

    by Nahdiya Laila Mufida, Arum Sinda Santika, Marissa Angelina, Dian Fitria Agustiyanti, Popi Hadi Wisnuwardhani, Yana Rubiyana, Ratih Asmana Ningrum, Andri Wardiana, Hariyatun Hariyatun, Ferry Iskandar, et al.

    The chemical crosslinking method has been effective in previous studies for interaction-based drug screening. Although CDs have been widely explored as antiviral candidates, studies that use chemical crosslinking to select effective CDs against SARS-CoV-2 remain limited. To address this gap, this study uses chemical crosslinking to test CDs as antiviral compounds. The objective of this study is to screen and determine the potential of CDs as candidate antiviral compounds for inhibiting the dimerization of the SARS-CoV-2 N-CTD protein using a chemical crosslinking method. Recombinant SARS-CoV-2 N-CTD protein was expressed, purified, and precipitated for compound testing with chemical crosslinking. The concentration ranges used in the dimerization inhibition testing were 0-2,000 ppm (pyrrolic-N CDs) and 0-6,000 ppm (pyridinic-N, graphitic-N, and nuciferine-derived CDs). The study’s results show that CDs have the potential to inhibit dimerization of the SARS-CoV-2 N-CTD protein. Among the four compounds tested, pyrrolic-N CDs showed the best inhibitory potential, as they inhibited dimerization at the lowest concentration (2,000 ppm), had the smallest percentage of dimer bands to total protein, and achieved the highest dimerization inhibition efficiency. However, further research, including in vitro and in vivo tests, is needed to comprehensively evaluate the potential of pyrrolic-N CDs.

  • Open Access

    Evaluation of Curcumin-derived Carbon-dots' Inhibitory Activity as SARS-CoV-2 Antiviral Candidate Using Chemical Crosslinking

    by Audrey Angelina Putri Taharuddin, Nicholas Yamahoki, Rebecca Stephanie, Dian Fitria Agustiyanti, Popi Hadi Wisnuwardhani, Marissa Angelina, Yana Rubiyana, Ratih Asmana Ningrum, Andri Wardiana, Desriani Desriani, et al.

    In our previous work, we demonstrated that curcumin-derived carbon dots (Cur-CDs) have potential as antivirals for COVID-19. However, the precise mechanism of action remains unclear. This study investigated the potential of Cur-CDs against SARS-CoV-2 by targeting the dimerization of the C-terminal domain of nucleocapsid protein (N-CTD) using chemical crosslinking. Recombinant SARS-CoV-2 N-CTD was expressed, purified, and subjected to chemical crosslinking. The dimerization inhibition ability of Cur-CDs was assessed with ligand concentrations ranging from 0 to 2,000 μg/mL. Successful inhibition —defined as a noticeable reduction in SARS-CoV-2 N-CTD dimer band intensity on SDS-PAGE—was observed when Cur-CDs were present at 8 to 16 times the protein concentration. We hypothesize that Cur-CDs bind to the dimerization residues, preventing non-covalent interactions between monomers and limiting dimer formation. Our findings suggest that Cur-CDs could be a promising antiviral strategy for SARS-CoV-2, especially targeting the dimerization of the nucleocapsid protein. Additionally, this study also highlights the use of chemical crosslinking as a valuable tool for interaction-based drug screening.